Investment group

GLX Analytix receives funding from DigitalDx Ventures, Vaekstfonden and CBC Investment Group to accelerate its growth

New Funding Will Help Accelerate Growth of GLX Analytix’s Innovative Glycocalyx-Focused Personalized Diagnostics Platform

We are thrilled to have investors who understand the need for early detection and monitoring of chronic diseases and our mission to bring personalized medicine to millions of people around the world.

—Brian Della Valle, CEO, GLX Analytix

SILICON VALLEY, California, United States, June 14, 2022 / — GLX Analytix today announced an investment from Silicon Valley-based DigitalDx Ventures, a health technology impact fund in seed phase, which will help accelerate the growth of the award-winning startup whose proprietary technology combines with a new class of biomarkers with artificial intelligence to improve personalized healthcare. GLX Analytix’s unique approach, with capabilities for early diagnosis, prediction and monitoring of autoimmune and neurodegenerative diseases, has the potential to improve the lives of patients worldwide.

DigitalDx Ventures is leading this funding round with additional investors, including Denmark’s largest venture capital firm, Vaekstfonden, and Swedish medtech venture capitalist, CBC Investment Group.

“Brian’s research and validation of the glycocalyx for early disease detection is a game-changer,” said Michele Colucci, Founder and Managing Partner of DigitalDx Ventures. “We are at a pivotal time in personalized healthcare, and GLX Analytix is ​​poised to dramatically improve the lives of patients with its innovative platform.”

“We are thrilled to have investors who understand the need for early detection and tracking of chronic disease and our mission to bring personalized medicine to millions of people around the world,” said Brian Della Valle. , CEO of GLX Analytix. “This investment will help fund the growth of our business and the translation of our early discoveries and validations into a market-ready product.”

About GLX Analytix: At GLX Analytix, we combine a proprietary new class of biomarkers with AI to bring personalized medicine to your healthcare. We envision a future where patients are diagnosed earlier, empowered to monitor themselves, and treatment plans are optimized. Our goal is to improve the lives of patients everywhere., [email protected]

Winner of the Roche Future of Healthcare Startup Award
“…this approach has clear potential to improve the lives of patients everywhere.”
– Dr. Tim M. Jaeger, Global Head of Diagnostic Information Solutions, Roche

About DigitalDx: DigitalDx Ventures is a Silicon Valley-based majority women-owned impact fund comprised of a team of successful Silicon Valley digital health investors and healthcare professionals who leverage AI and big data technologies to diagnose major global health issues (such as breast cancer and other cancers). , cardiovascular and renal health, Alzheimer’s disease and mental health) with a particular focus on the early, more precise and less invasive diagnosis of the disease.

About Vaekstfonden: Vaekstfonden is Denmark’s sovereign wealth fund, which aims to discover and grow the businesses that Denmark cannot afford to miss. Vaekstfonden Investment manages a direct investment portfolio of over 70 companies, from early stage start-ups to mature growth scale-ups. Working closely with domestic and international private investors, Vaekstfonden’s investment professionals actively contribute to portfolio companies in three particular segments: Tech/Industry, Agribusiness/Energy and Life Sciences.

About CBC Investment Group: CBC Investment Group is a venture capital firm based in Gothenburg, Sweden, which invests in medical technology and digital health companies in the Nordic countries.

Stefanie Beasley, Partner
Beasley McCusker Communications
+1 415-867-6575
write to us here
Visit us on social media: